These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3308485)

  • 41. Preclinical antitumor activity of orally administered platinum (IV) complexes.
    Rose WC; Crosswell AR; Schurig JE; Casazza AM
    Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth and chemotherapy of a human germ-cell tumour line (GCT 27).
    Schlappack OK; Bush C; Delic JI; Steel GG
    Strahlenther Onkol; 1989 Jul; 165(7):541. PubMed ID: 2473535
    [No Abstract]   [Full Text] [Related]  

  • 43. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New platinum agents. A comparison in ovarian cancer.
    Kelland LR; McKeage MJ
    Drugs Aging; 1994 Aug; 5(2):85-95. PubMed ID: 7981487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carboplatin in the treatment of ovarian cancer.
    Alberts DS; Mason-Liddil N
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carboplatin versus cisplatin.
    Tighe M; Goodman S
    Lancet; 1988 Dec; 2(8624):1372-3. PubMed ID: 2904096
    [No Abstract]   [Full Text] [Related]  

  • 47. Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.
    Hida S; Okada K; Yoshida O
    Jpn J Cancer Res; 1990 Apr; 81(4):425-30. PubMed ID: 2114395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
    Jones AC; Wilson PA; Steel GG
    Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treating ovarian cancer.
    Sweetenham JW; Mead GM; Whitehouse JM; Williams CJ
    Br Med J (Clin Res Ed); 1986 Nov; 293(6559):1435-6. PubMed ID: 3099901
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
    Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
    Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
    Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Whither carboplatin.
    J Clin Oncol; 1987 Jun; 5(6):984-6. PubMed ID: 3295133
    [No Abstract]   [Full Text] [Related]  

  • 53. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
    Burbridge MF; Kraus-Berthier L; Naze M; Pierre A; Atassi G; Guilbaud N
    Int J Oncol; 1999 Dec; 15(6):1155-62. PubMed ID: 10568822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
    Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
    Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
    Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
    Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
    Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Combination chemotherapy of paclitaxel followed by nedaplatin for human ovarian cancer].
    Uchida N; Yamada H; Maekawa R; Yoshioka T
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1943-9. PubMed ID: 12465394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of the renal function in patients with ovarian carcinoma subjected to polychemotherapy including cisplatin or carboplatin].
    Gadducci A; Facchini V; Dell'Arciprete T; Del Bravo B; Galigani P; Palla R; Fioretti P
    Minerva Ginecol; 1988 Jan; 40(1):33-8. PubMed ID: 3287233
    [No Abstract]   [Full Text] [Related]  

  • 60. The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.
    Fish RG; Shelley MD; Maughan T; Rocker I; Adams M
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):831-5. PubMed ID: 3308479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.